The benefit of the SGLT2 inhibitor empagliflozin in patients with HF with preserved ejection fraction did not differ between those who did or did not receive mineralocorticoid receptor antagonists, researchers reported.In a prespecified secondary analysis of the EMPEROR-Preserved trial of patients with HFpEF, researchers found that while the effect of empagliflozin (Jardiance, Boehringer